Can-Fite BioPharma Files 2024 Annual Report

Ticker: CANF · Form: 20-F · Filed: Apr 14, 2025 · CIK: 1536196

Can-Fite Biopharma LTD. 20-F Filing Summary
FieldDetail
CompanyCan-Fite Biopharma LTD. (CANF)
Form Type20-F
Filed DateApr 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: annual-report, pharmaceuticals, sec-filing

TL;DR

Can-Fite BioPharma dropped its 2024 annual report, check it for the latest on their pharma biz.

AI Summary

Can-Fite BioPharma Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is involved in the pharmaceutical preparations industry. Its principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, Israel.

Why It Matters

This filing provides investors with a comprehensive overview of Can-Fite BioPharma's financial performance and business operations for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Can-Fite BioPharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Can-Fite BioPharma Ltd.?

Can-Fite BioPharma Ltd. is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].

When is the fiscal year end for Can-Fite BioPharma Ltd.?

The fiscal year end for Can-Fite BioPharma Ltd. is December 31.

Where are Can-Fite BioPharma Ltd.'s principal offices located?

Can-Fite BioPharma Ltd.'s business and mail address is 26 Ben Gurion Street, Ramat Gan, Israel.

What type of filing is this for Can-Fite BioPharma Ltd.?

This filing is an Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the SEC file number for Can-Fite BioPharma Ltd.?

The SEC file number for Can-Fite BioPharma Ltd. is 001-36203.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on April 14, 2025 regarding Can-Fite BioPharma Ltd. (CANF).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing